The proportion of early-stage drug trials tackling the biggest cancer killers has declined sharply since the early 1990s as less common tumor types receive increasing attention, according to new research to be presented during the International Congress on Targeted Anticancer Therapies 2019, taking place from today to 27 February in Paris, France.
More...